In this study, our objective was to analysis the association of CYP3A4* 1G, CYP3A5* 3 and MDR1 C3435T gene polymorphisms with the antihypertensive efficacy of amlodipine in hypertensive patients after renal transplantation.Design and Method:
Blood samples were collected from 76 patients on amlodipine (5 mg/d) therapy. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and gene sequencing were applied to detect CYP3A4* 1G, CYP3A5* 3 and MDR1 C3435T gene polymorphism and antihypertensive effects were analyzed according to genotype. At the same time, blood pressure values were detected per week and recorded.Results:
After 4- weeks treatment, the blood pressure of 79% patients were controlled to standard. And the efficacy of amlodipine in patients with CYP3A5 *3*3 genotype was significantly higher than others (P < 0.05). In addition, the reduction of DBP in patients with CYP3A5*3*3 genotype was significantly higher than others (P < 0.05), the reduction of DBP in patients with CYP3A4*1G*1G genotype was significantly lower than the othera (P < 0.05). As for a linkage disequilibrium exists between CYP3A4* 1G and CYP3A5* 3 allele, our study also observed that DBP reduction in GG GG genetypes was the highest in all genetypes.Conclusions:
Our study demonstrates that amlodipine could control BP effectively for hypertensive patients after renal transplantation. CYP3A5* 3 polymorphisms affect antihypertensive efficacy of amlodipine in Chinese hypertensive patients after renal transplantation.